Abstract:BACKGROUND: The molecular mechanisms underlying denervated skeletal muscle atrophy with concomitant muscle mass loss have not been fully elucidated. Therefore, this study aimed to attain a deeper understanding of the molecular mechanisms underlying denervated skeletal muscle atrophy as a critical step to developing targeted therapy and retarding the concomitant loss of skeletal muscle mass.METHODS: We employed microarray analysis to reveal the potential molecular mechanisms underlying denervated skeletal muscle atrophy. We used in vitro and in vivo atrophy models to explore the roles of the interleukin 6 (IL-6), Janus kinase (JAK), and signal transducers and activators of transcription 3 (STAT3) in muscle atrophy.RESULTS: In this study, microarray analysis of the differentially expressed genes demonstrated that inflammation-related cytokines were markedly triggered and IL-6/JAK/STAT3 signaling pathway was strongly activated during denervated skeletal muscle atrophy. The high level of IL-6 enhanced C2C12 myotube atrophy through the activation of JAK/STAT3, while inhibiting JAK/STAT3 pathway by ruxolitinib (a JAK1/2 inhibitor) or C188-9 (a STAT3 inhibitor) significantly attenuated C2C12 myotube atrophy induced by IL-6. Pharmacological blocking of IL-6 by tocilizumab (antibody against IL-6 receptor) and pharmacological/genetic inhibition of JAK/STAT3 pathway by ruxolitinib/C188-9 (JAK/STAT3 inhibitor) and STAT3 short hairpin RNA (shRNA) lentivirus in tibialis anterior muscles could suppress muscle atrophy and inhibit mitophagy, and was accompanied by the decreased expression of atrophic genes (MuRF1 and MAFbx) and autophagy-related genes (PINK1, BNIP3, Beclin 1, ATG7, and LC3B).CONCLUSIONS: Taken together, the results suggest that IL-6/JAK/STAT3 pathway may be a principal mediator in denervated skeletal muscle atrophy, meaning targeted therapy against IL-6/JAK/STAT3 pathway might have potential as a therapeutic strategy for prevention of skeletal muscle atrophy.

STAT3 induces muscle stem cell differentiation by interaction with myoD.

JAK1–STAT1–STAT3, a key pathway promoting proliferation and preventing premature differentiation of myoblasts

Stage-specific Effects of Notch Activation During Skeletal Myogenesis

Stat3 Exerts Two-Way Regulation In The Biological Effects Of Il-6 In M1 Leukemia Cells

MYOD induced lnc-MEG3 promotes porcine satellite cell differentiation via interacting with DLST

miR-9-5p promotes myogenic differentiation via the Dlx3/Myf5 axis

STAT3 Protein Regulates Vascular Smooth Muscle Cell Phenotypic Switch by Interaction with Myocardin

METTL3-Mediated m6A Methylation Regulates Muscle Stem Cells and Muscle Regeneration by Notch Signaling Pathway

MicroRNA‐323‐3p Promotes Myogenesis by Targeting Smad2

STAT3 is Required for Proliferation and Exhibits a Cell Type-Specific Binding Preference in Mouse Female Germline Stem Cells

The Jak2/Stat3 Signal Pathway Regulates The Expression Of Genes Related To Skeletal Muscle Development And Energy Metabolism In Mice And Mouse Skeletal Muscle Cells

Expression of Myogenin and MCK Genes Regulated by PI3K/AKT Pathway

METTL3 Promotes Proliferation and Myogenic Differentiation Through M6a RNA Methylation/ythdf1/2 Signaling Axis in Myoblasts

Stat3 Activation is Critical for Pluripotency Maintenance

STAT3 Inhibits Myocardin Induced Cardiac Hypertrophy

The transcriptional co-repressor TLE3 regulates myogenic differentiation by repressing the activity of the MyoD transcription factor

Selective Activation of STAT3 and STAT5 Dictates the Fate of Myeloid Progenitor Cells

Roles Of Stat3 In Regulation Of Emt-Mediated Phenotypic Plasticity And Its Effects On Circulating Tumor Cells And Tumor Invasion And Metastases

Oncostatin M Inhibits Myoblast Differentiation and Regulates Muscle Regeneration

The Mediator Med23 controls a transcriptional switch for muscle stem cell proliferation and differentiation in muscle regeneration

Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy